ArticleInternal and emergency medicine2018
NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
Article in Internal and emergency medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Self-report instruments for assessing adherence to warfarin therapy: a systematic review.European journal of clinical pharmacology · 2021Pooled it
- Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy.Journal of clinical medicine · 2021Article
- Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation.Internal and emergency medicine · 2021Observational
- Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation.Internal and emergency medicine · 2020Article
- Managing atrial fibrillation: the need for an individualized approach even in the emergency department.Internal and emergency medicine · 2020Article
- Is delayed cardioversion the better approach in recent-onset atrial fibrillation? No.Internal and emergency medicine · 2020Article
- Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Internal and emergency medicine · 2019Article
- Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.Internal and emergency medicine · 2019Article
- The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey.Internal and emergency medicine · 2018Article
- A focus on direct oral anticoagulants: "old" and possible new indications and efforts for a better clinical management.Internal and emergency medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past few years, new oral anticoagulants (NOACs) targeting directly a single activated clotting factor, have been developed for the treatment of non-valvular atrial fibrillation (AF), which are currently recommended as first-line therapy in AF. The aim of this study is to provide an overall picture on the extent to which oral anticoagulation (OAC) with NOACs correspond to actually prescribed OAC therapy in an unselected, real world, population of consecutive patients with AF in Italy. Compliance with the therapy and quality of life were also assessed. A 50 cardiology unit network located in different geographic areas of Italy enrolled a total of 1742 consecutive outpatients with AF (54.6% males, 45.4% females, mean age 72.5 years). NOACs were prescribed in 56.1% patients and VKA in 43.9% (P < 0.0001). NOACs were significantly more prescribed than VKA in patients with high thrombo-embolic risk score (i.e., CHA
Indexed as
Identifiers
29956065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.